1. abnormal vital signs that are clinically significant (e.g. abnormal controlled blood pressure); 2. have been infected with covid-19 or used any covid-19 prophylactic medication other than 3 doses of covid-19 inactivated vaccine within the last 6 months (for example, a history of any other non-covid-19 inactivated vaccine on or off the market, or 1 or 4 doses of covid-19 inactivated vaccine); 3. history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers) and other human coronavirus infection or disease history; 4. axillary temperature ≥37.3℃ or fever within 24 hours on the day of vaccination (axillary temperature ≥37.3℃/ mouth temperature ≥37.5℃); 5. a history of severe allergic reactions or allergic reactions to vaccines or drugs, such as urticaria, severe eczema, dyspnea, laryngeal edema, angioneurotic edema, etc.; 6. vaccination of any vaccine within 28 days prior to study vaccination; 7. enrolled in a clinical study of another drug within 28 days before vaccination or planned to participate in a clinical study of another drug within 6 months after vaccination; 8. have a genetic tendency to bleed or abnormal coagulation function (e.g. cytokine deficiency, coagulation disorder or thrombocytopenia), or a history of severe bleeding; 9. a known history or diagnosis of a disease affecting immune system function, such as cancer (other than basal cell carcinoma of the skin), congenital or acquired immunodeficiency (e.g., hiv infection), uncontrolled autoimmune disease, etc.; 10. asplenia or functional asplenia; 11. long-term use (continuous use ≥14 days) of immunosuppressants or other immunomodulatory drugs (e.g., cortisol: prednisone or similar drugs) within 6 months prior to study vaccination; interferon, etc.), but topical use (such as ointments, eye drops, inhalants or nasal sprays) is permitted, and the dose of topical use shall not exceed that recommended in the instructions; 12. received immunoglobulin and/or blood products within 3 months prior to study vaccination; 13. suspected or known alcohol dependence or drug abuse; 14. other factors considered inappropriate to be included in the study.

1. abnormal vital signs that are clinically significant (e.g. abnormal controlled blood pressure); 2. have been infected with covid-19 or used any covid-19 prophylactic medication other than 3 doses of covid-19 inactivated vaccine within the last 6 months (for example, a history of any other non-covid-19 inactivated vaccine on or off the market, or 1 or 4 doses of covid-19 inactivated vaccine); 3. history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers) and other human coronavirus infection or disease history; 4. axillary temperature ≥37.3℃ or fever within 24 hours on the day of vaccination (axillary temperature ≥37.3℃/ mouth temperature ≥37.5℃); 5. a history of severe allergic reactions or allergic reactions to vaccines or drugs, such as urticaria, severe eczema, dyspnea, laryngeal edema, angioneurotic edema, etc.; 6. vaccination of any vaccine within 28 days prior to study vaccination; 7. enrolled in a clinical study of another drug within 28 days before vaccination or planned to participate in a clinical study of another drug within 6 months after vaccination; 8. have a genetic tendency to bleed or abnormal coagulation function (e.g. cytokine deficiency, coagulation disorder or thrombocytopenia), or a history of severe bleeding; 9. a known history or diagnosis of a disease affecting immune system function, such as cancer (other than basal cell carcinoma of the skin), congenital or acquired immunodeficiency (e.g., hiv infection), uncontrolled autoimmune disease, etc.; 10. asplenia or functional asplenia; 11. long-term use (continuous use ≥14 days) of immunosuppressants or other immunomodulatory drugs (e.g., cortisol: prednisone or similar drugs) within 6 months prior to study vaccination; interferon, etc.), but topical use (such as ointments, eye drops, inhalants or nasal sprays) is permitted, and the dose of topical use shall not exceed that recommended in the instructions; 12. received immunoglobulin and/or blood products within 3 months prior to study vaccination; 13. suspected or known alcohol dependence or drug abuse; 14. other factors considered inappropriate to be included in the study.

abnormal vital signs that are clinically significant (e.g. abnormal controlled blood pressure); have been infected with covid-19 or used any covid-19 prophylactic medication other than 3 doses of covid-19 inactivated vaccine within the last 6 months (for example, a history of any other non-covid-19 inactivated vaccine on or off the market, or 1 or 4 doses of covid-19 inactivated vaccine); history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers) and other human coronavirus infection or disease history; axillary temperature ≥37.3℃ or fever within 24 hours on the day of vaccination (axillary temperature ≥37.3℃/ mouth temperature ≥37.5℃); a history of severe allergic reactions or allergic reactions to vaccines or drugs, such as urticaria, severe eczema, dyspnea, laryngeal edema, angioneurotic edema, etc.; vaccination of any vaccine within 28 days prior to study vaccination; enrolled in a clinical study of another drug within 28 days before vaccination or planned to participate in a clinical study of another drug within 6 months after vaccination; have a genetic tendency to bleed or abnormal coagulation function (e.g. cytokine deficiency, coagulation disorder or thrombocytopenia), or a history of severe bleeding; a known history or diagnosis of a disease affecting immune system function, such as cancer (other than basal cell carcinoma of the skin), congenital or acquired immunodeficiency (e.g., hiv infection), uncontrolled autoimmune disease, etc.; asplenia or functional asplenia; long-term use (continuous use ≥14 days) of immunosuppressants or other immunomodulatory drugs (e.g., cortisol: prednisone or similar drugs) within 6 months prior to study vaccination; interferon, etc.), but topical use (such as ointments, eye drops, inhalants or nasal sprays) is permitted, and the dose of topical use shall not exceed that recommended in the instructions; received immunoglobulin and/or blood products within 3 months prior to study vaccination; suspected or known alcohol dependence or drug abuse; other factors considered inappropriate to be included in the study.

abnormal vital signs that are clinically significant (e.g. abnormal controlled blood pressure); have been infected with covid-19 or used any covid-19 prophylactic medication other than 3 doses of covid-19 inactivated vaccine within the last 6 months (for example, a history of any other non-covid-19 inactivated vaccine on or off the market, or 1 or 4 doses of covid-19 inactivated vaccine); history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers) and other human coronavirus infection or disease history; axillary temperature ≥37.3℃ or fever within 24 hours on the day of vaccination (axillary temperature ≥37.3℃/ mouth temperature ≥37.5℃); a history of severe allergic reactions or allergic reactions to vaccines or drugs, such as urticaria, severe eczema, dyspnea, laryngeal edema, angioneurotic edema, etc.; vaccination of any vaccine within 28 days prior to study vaccination; enrolled in a clinical study of another drug within 28 days before vaccination or planned to participate in a clinical study of another drug within 6 months after vaccination; have a genetic tendency to bleed or abnormal coagulation function (e.g. cytokine deficiency, coagulation disorder or thrombocytopenia), or a history of severe bleeding; a known history or diagnosis of a disease affecting immune system function, such as cancer (other than basal cell carcinoma of the skin), congenital or acquired immunodeficiency (e.g., hiv infection), uncontrolled autoimmune disease, etc.; asplenia or functional asplenia; long-term use (continuous use ≥14 days) of immunosuppressants or other immunomodulatory drugs (e.g., cortisol: prednisone or similar drugs) within 6 months prior to study vaccination; interferon, etc.), but topical use (such as ointments, eye drops, inhalants or nasal sprays) is permitted, and the dose of topical use shall not exceed that recommended in the instructions; received immunoglobulin and/or blood products within 3 months prior to study vaccination; suspected or known alcohol dependence or drug abuse; other factors considered inappropriate to be included in the study.